metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALE...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Full text access
OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALERTS ON ETHNICAL DISPARITIES IN TUMOR PRESENTATION AND OUTCOME
Visits
35
Leonardo G Da Fonseca1Laura Izquierdo Sanchez2Pedro H Hashizume1Yanina Carlino3Estefanía Liza Baca4Cristina Zambrano5Santiago Sepulveda6Andrea Bolomo3Pedro M Rodrigues7Ioana Riaño7Andre Boonstra8Jose D Debes9Luis Bujanda7Flair J Carrilho1Marco Arrese6Juan C Roa6Enrique Carrera10Javier Díaz Ferrer4Domingo Balderramo3Claudia P Oliveira11Jesus M Banales7
1 Instituto do Cancer do Estado de Sao Paulo (ICESP), SAO PAULO, Brasil
2 IIS BIOGIPUZKOA, SAN SEBASTIAN, España
3 Hospital Privado Universitario de Córdoba, CORDOBA, Argentina
4 Hospital Nacional Edgardo Rebagliati Martins-Essalud, LIMA, Perú
5 Hospital de Especialidades Carlos Andrade Marín, QUITO, Ecuador
6 Pontificia Universidad Católica de Chile, SANTIAGO DE CHILE, Chile
7 Biogipuzkoa Health Research Institute - Donostia University Hospital, SAN SEBASTIAN, España
8 Erasmus MC University Medical Center, ROTTERDAM, Holanda (see netherlands)
9 University of Minnesota, MINNESOTA, Estados Unidos (EEUU)
10 Hospital Especialidades Eugenio Espejo, QUITO, Ecuador
11 Universidade de São Paulo São Paulo, SAO PAULO, Brasil
Ver más
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2024 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

Cholangiocarcinoma (CCA) represents a global health challenge, with rising incidence and mortality rates. This study aimed to elucidate the clinical course and practices of CCA in Latin America.

Patients / Materials and Methods

This observational cohort study investigated individuals diagnosed with CCA between 2010-2023 in five referral centers across Latin America. Demographic, biochemical, and clinical data were analyzed.

Results and Discussion

A total of 309 patients were enrolled, demonstrating a balanced distribution of CCA subtypes (intrahepatic, perihilar, and distal), with Hispanics and Caucasians as the predominant ethnic groups, followed by Africans. Major risk factors identified included age, diabetes, obesity, MASLD, bile duct stones, and cholecystitis. Disparities in overweight/obesity prevalence were noted among CCA subtypes and ethnicities, with higher rates in extrahepatic CCAs and among Hispanics and Caucasians. At diagnosis, 72% of patients had ECOG-PS scores of 0-1, with disease presentations ranging from localized (47%) to locally advanced (19%) and metastatic (34%). Patients who did not receive any anti-cancer therapy exhibited a median survival of 2.3 months. Survival rates significantly improved across treatment modalities, with surgery yielding the longest (34 months), followed by chemotherapy (8 months). Notably, Africans presented with worse ECOG-PS scores and more advanced disease, while Hispanics were less frequently treated with chemotherapy, contributing to lower survival rates.

Conclusions

The high prevalence of late-stage CCA diagnosis in Latin America, particularly among Africans, alongside a substantial proportion of Hispanic patients not receiving chemotherapy, underscores a dismal prognosis for patients. These findings highlight structural challenges in cancer screening and healthcare access among diverse ethnic backgrounds and lower socioeconomic statuses in the region. Urgent measures are warranted, including identifying preventable risk factors, increasing awareness among high-risk populations, and establishing equitable health coverage to address these disparities.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2021.100376
No mostrar más